Trial Profile
A Phase 1 Study to Evaluate the Safety and Clinical Activity of Intravesicular CAVATAK (Coxsackievirus A21, CVA21) Alone and in Sequential Combination With Low Dose Mitomycin C in Patients With Non-Muscle Invasive Bladder Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Gebasaxturev (Primary) ; Mitomycin
- Indications Bladder cancer
- Focus Adverse reactions
- Acronyms CANON
- Sponsors Viralytics
- 04 Jul 2019 Results assessing safety, feasibility and biological effects of escalating intravesical doses of CVA21 in first-line non-muscle invasive bladder cancer patients published in the Clinical Cancer Research
- 11 Oct 2016 Results assessing tumor response presented at the 41st European Society for Medical Oncology Congress (2016).
- 31 Jul 2016 Status changed from active, no longer recruiting to completed.